Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

Apr 30, 2018

BUY
$260.13 - $367.91 $171,685 - $242,820
660 Added 13.68%
5,485 $1.51 Million
Q4 2017

Feb 13, 2018

BUY
$307.64 - $344.58 $1.48 Million - $1.66 Million
4,825
4,825 $1.54 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $20.2B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track James Hambro & Partners Portfolio

Follow James Hambro & Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of James Hambro & Partners, based on Form 13F filings with the SEC.

News

Stay updated on James Hambro & Partners with notifications on news.